maintain underweight consid med-tech darl
dont disagre ew impress busi fundament transcathet aortic
valv replac tavr life-chang technolog weve seen result first
hand howev stock perspect believ share overvalu rel
current futur growth profil see unfavor risk/reward point
ip litig risk abt patent infring case ew uk kick
monday us trial set next may earlier week us patent trial appeal board
deni ew request institut inter part review ipr patent
transcathet mitral valv tmvr/r opportun far away take time
develop well ew work tmvr/r decad
numer fail ew program well other industri
mobiu edge-to-edg stitch approach pascal discontinu
monarch annuloplasti approach acquir cardioband discontinu
circa cardioband redesign forti cardiaq
current sapien evoqu design still seem evolv
ew defici rather mv mv diseas complex
leader challeng field litter dozen failur
ew expect pascal clasp iid trial complet enrol year-end
could yield fda approv ip litig asid keep mind
narrow indic prohibit risk degen mr broader indic
like data point sapien corevalv mitraclip approv europ
time late ww sale today tavr tmvr
meantim deceler growth usual mean pe compress
increas pt reflect higher ep
maintain pe multipl reason premium
high growth med-tech name dont believ current pe warrant
ew quarterli annual ep usd
consensu number bloomberg receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
rais usd
return equiti ttm
idc link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
underweight believ sale growth like
slow edward face competit transcathet
aortic valv tavr expect limit leverag
edward invest transcathet mitral valv
tmvr/r opportun sale ep estim
street tmvr/r repres potenti
second act still risk like
upsid case may driven better-than-
expect tavr sale greater leverag
stronger uptak tmvr europ faster-
than-expect time tmvr/r product
downsid case may driven delay
inabl commerci tmvr/r technolog
slowdown tavr sale due market slowdown
and/or competit pressur fx rate
greater expens support tmvr/r
recap note investor day pleas see follow
kristen stewart cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
unless otherwis indic price sourc bloomberg reflect close price relev trade market may
last avail price time public
